TAC Health Card | Hypercholesterolemia target validation
T layer — Mechanistic evidence
Status: STRONG
PCSK9 regulates LDL receptor degradation and directly influences circulating LDL cholesterol levels.
Mechanistically, inhibition of PCSK9 increases LDL receptor availability and enhances clearance of LDL particles from circulation.
The causal relationship between PCSK9 activity and lipid control is well established.
Φ layer — Genetic evidence
Status: STRONG
Human genetics strongly validate PCSK9 as a causal target.
Gain-of-function variants are associated with familial hypercholesterolemia, while loss-of-function variants are associated with lower LDL levels and reduced cardiovascular risk.
This is one of the clearest examples of target validation supported by human genetic evidence.
Σ layer — Clinical evidence
Status: STRONG
Clinical inhibition of PCSK9 has consistently reduced LDL cholesterol and improved cardiovascular outcomes.
Approved agents such as evolocumab and alirocumab demonstrated strong translational performance from mechanism through clinical intervention.
Clinical evidence supports both biomarker improvement and patient-level benefit.
Alignment topology
TΦΣ
Pattern: full cross-layer alignment
Decision interpretation
PCSK9 represents a canonical success case in target validation.
Mechanistic reasoning, human genetics, and clinical intervention all point in the same direction.
Cross-layer evidence alignment indicates low translational risk and high decision confidence.
Why this case matters
PCSK9 is a reference example of what strong Evidence Alignment looks like in practice.
It demonstrates how human genetics can de-risk mechanism-based drug discovery when supported by coherent clinical translation.